Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.

Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery ...

UK pharma major AstraZeneca today revealed that, this week, it has received two positive recommendations from the National ...

The Lazcluze plus Rybrevant combination could challenge AstraZeneca’s standard-of-care Tagrisso in non-small cell lung cancer ...

In final draft guidance, NICE said Tagrisso (osimertinib) should be funded by the NHS until new data emerges about the long-term benefits of the drug. However there have been many misgivings ...

AstraZeneca has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for ...

A DAILY pill that doubles survival time for lung cancer patients will be made routinely available on the NHS. Osimertinib, also known as Tagrisso and made by AstraZeneca, helps prevent cancer from ...

The drug was previously available through the Cancer Drugs Fund, but with more data, NICE is backing routine access through the NHS.

AstraZeneca has gained approval from the European Commission (EC) for its oral therapy, Tagrisso (osimertinib), to treat adults with locally advanced, unresectable non-small cell lung cancer (NSCLC).

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) for use of its lung cancer drugs Tagrisso (osimertinib) and Imfinzi ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...